Figure 5. In vivo efficacy of the androgen receptor antagonist enzalutamide (XTANDI) in U87MG human glioblastoma xenografts.

A total 5×10⁶ tumor cells were inoculated subcutaneously into athymic nude mice, which were randomly assigned to vehicle (n=18) and XTANDI (n=8) treated groups. Treatment started on day 7 when the tumors had grown to an approximate 50-mm3volume. The mice were gavaged orally every second day with 20/mg/kg XTANDI or vehicle (220mg/kg caprylocaproyl polyoxylglycerides CH in saline). Each point, representing median tumor volume ± SEM, is shown with polynomial curve fitting.